|
Investigational Asthma Treatment Cuts Exacerbation Rates in Half
Pharmacy Times (registration) The study compared the anti-interleukin-5 (IL-5) monoclonal antibody, reslizumab, with placebo in 953 patients with both asthma and elevated blood eosinophil levels. The research team found that patients treated with reslizumab in the first study … |
View full post on asthma – Google News